Abstract
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) randomized over 35 000 men into four groups: high-dose vitamin E (400 IU day−1), high-dose selenium (200 mcg day−1), combination of vitamin E and selenium, or placebo.1 The brief time period to reach full recruitment was unprecedented; thus, it seemed that participants and health-care professionals were equally eager to test the hypothesis that high-dose antioxidant supplementation could prevent prostate cancer. However, the trial was terminated early, after a median of 5.5 years due to a lack of efficacy, although at the time a non-significant (P=0.06) increased risk of prostate cancer in the vitamin E arm, and type 2 diabetes in the selenium group (P=0.16) were observed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
